Bank of America’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-1
| Closed | – | – | 8719 |
|
|
2022
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 8483 |
|
|
2022
Q2 | $0 | Sell |
1
-861
| -100% | -$435 | ﹤0.01% | 8716 |
|
|
2022
Q1 | $1K | Sell |
862
-3,835
| -82% | -$4.21K | ﹤0.01% | 8178 |
|
|
2021
Q4 | $11K | Sell |
4,697
-2,009
| -30% | -$6.8K | ﹤0.01% | 7688 |
|
|
2021
Q3 | $31K | Sell |
6,706
-3,385
| -34% | -$14.9K | ﹤0.01% | 7253 |
|
|
2021
Q2 | $45K | Sell |
10,091
-20,585
| -67% | -$105K | ﹤0.01% | 6890 |
|
|
2021
Q1 | $223K | Buy |
30,676
+17,768
| +138% | +$146K | ﹤0.01% | 5956 |
|
|
2020
Q4 | $99K | Buy |
12,908
+6,057
| +88% | +$40.5K | ﹤0.01% | 5999 |
|
|
2020
Q3 | $62K | Buy |
6,851
+1,711
| +33% | +$13K | ﹤0.01% | 5930 |
|
|
2020
Q2 | $43K | Buy |
5,140
+2,351
| +84% | +$15.5K | ﹤0.01% | 6047 |
|
|
2020
Q1 | $14K | Sell |
2,789
-670
| -19% | -$5.21K | ﹤0.01% | 6274 |
|
|
2019
Q4 | $25K | Sell |
3,459
-955
| -22% | -$8.63K | ﹤0.01% | 6452 |
|
|
2019
Q3 | $48K | Buy |
4,414
+520
| +13% | +$5.56K | ﹤0.01% | 6337 |
|
|
2019
Q2 | $51K | Sell |
3,894
-740
| -16% | -$9.82K | ﹤0.01% | 6297 |
|
|
2019
Q1 | $45K | Buy |
4,634
+1,278
| +38% | +$11.9K | ﹤0.01% | 6240 |
|
|
2018
Q4 | $34K | Buy |
+3,356
| New | +$40.5K | ﹤0.01% | 6346 |
|
Bank of America's LOGC Position: Q4 2022 in Review
Bank of America sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 1 share.
Bank of America first reported a position in LOGC in Q4 2018 and held it in 16 quarters. The position peaked at $223K in Q1 2021. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.
- Bank of America reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
- Bank of America sold 1 LogicBio Therapeutics, Inc. Common Stock share in Q4 2022.
- Bank of America first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2018 and held it in 16 quarters.
- Bank of America's LogicBio Therapeutics, Inc. Common Stock position peaked at $223K in Q1 2021.
- 0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.
Based on Bank of America's 13F filing for Q4 2022, filed 10 Feb 2023.